Jun 12,2019

Study: Combination of self-monitoring blood glucose device & DTx improve patient outcomes

At the 79th Annual Scientific Sessions of the American Diabetes Association in San Francisco, pharma giant Roche and India-based digital therapeutics company Wellthy Therapeutics presented real world data of improved diabetes care outcomes in a South Asian population when patients followed prescribed plan of medication and lifestyle modification in conjunction with a combination therapy of self-monitoring blood glucose device and a clinically validated digital therapeutic (DTx).

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Jun 26,2019

Omada Health takes in $73M more in new funding round

San Francisco-based digital chronic disease management company Omada Health has closed a $73 million funding round led by Wellington Management Company. Cigna Ventures, Andreessen Horowitz, U.S. Venture Partners, Norwest Venture Partners, Kaiser Permanente Ventures, Sanofi Ventures, Civilization Ventures and Providence Ventures also contributed.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Jun 01,2019

ADA Sessions Offer News on Diabetes Technology

The 79th Scientific Sessions of the American Diabetes Association (ADA) offered plenty of news from the technology front—both studies about emerging products and updates on those already on the market. ADA included advances in diabetes technology in a special briefing, and there was plenty happening both on and off the exhibit floor. You can find some details about the presentations here.

View Analyst & Ambassador Comments
Go to original news
Jun 07,2019

Tandem Diabetes Care Announces Conference Call Following Data Presentations at the ADA Scientific Sessions

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will hold a conference call on Sunday, June 9, 2019 at 8:00pm Eastern Time (5:00pm Pacific Time) following data presentations at the 79th Scientific Sessions of the American Diabetes Association on its t:slim X2 with Control-IQ technology system.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 08,2019

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HBA1C LEVELS IN PEOPLE LIVING WITH TYPE 2 DIABETES

Presented as a late-breaker at the American Diabetes Association (ADA) 79th Scientific Sessions, new real-world data demonstrate that monitoring glucose with FreeStyle Libre System has a positive impact among adults with Type 2 Diabetes who use multiple injections of insulin daily.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 17,2019

ABBOTT LAUNCHES FIRST-EVER RAPID POINT-OF-CARE HBA1C TEST TO AID IN THE DIAGNOSIS OF DIABETES

Abbott (NYSE: ABT) today announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the condition.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jun 17,2019

Nemaura Provides Fiscal 2019 Year-End Business Update

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing SugarBEAT®, a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided a business update for the fiscal year ending March 31, 2019 and reported on recent corporate developments.

View Analyst & Ambassador Comments
Go to original news
Jun 19,2019

ABBOTT HOSTS CONFERENCE CALL FOR SECOND-QUARTER EARNINGS

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

View Analyst & Ambassador Comments
Go to original news
Jun 19,2019

19 Jun, 2019 Brighter has received ISO 13485 certification.

Brighter's quality management system has now been certified under ISO 13485. The same Notified Body that issues the certificate is working with the Actiste CE marking (EC-Certification). That process is in its final phase.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 20,2019

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 in New York at 1:20pm Eastern Time (10:20am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES